We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+44.97%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.38B
AUM Growth
+$1.14B
Cap. Flow
+$493M
Cap. Flow %
14.6%
Top 10 Hldgs %
62.24%
Holding
58
New
13
Increased
11
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$180M
2
NVTA
Invitae Corporation
NVTA
+$156M
3
BLFS icon
BioLife Solutions
BLFS
+$54.6M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$24.7M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$119M
2
AMRS
Amyris Inc.
AMRS
+$23.6M
3
ILMN icon
Illumina
ILMN
+$9.27M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$7.69M
5
LEGN icon
Legend Biotech
LEGN
+$4.31M

Sector Composition

Rank Sector Weight
1 Healthcare 84.21%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
26
DELISTED
Global Blood Therapeutics, Inc.
GBT
$35.1M 1.04%
810,000
+415,000
+105% +$20.5M
FDMT icon
27
4D Molecular Therapeutics
FDMT
$527M
$32.4M 0.96%
+780,555
New +$32.2M
DNTH icon
28
Dianthus Therapeutics
DNTH
$5.8B
$26.2M 0.78%
209,127
– –
ZLAB icon
29
Zai Lab
ZLAB
$2.05B
$25.7M 0.76%
190,000
– –
IOVA icon
30
Iovance Biotherapeutics
IOVA
$1.93B
$25.5M 0.76%
550,000
+260,000
+90% +$10.3M
ALEC icon
31
Alector
ALEC
$168M
$25M 0.74%
1,650,000
– –
ALLO icon
32
Allogene Therapeutics
ALLO
$635M
$23.9M 0.71%
945,000
– –
MASS icon
33
908 Devices
MASS
$345M
$23.1M 0.69%
+406,502
New +$23.7M
TSHA icon
34
Taysha Gene Therapies
TSHA
$1.66B
$21.8M 0.65%
820,440
– –
ORIC icon
35
Oric Pharmaceuticals
ORIC
$1.1B
$20.4M 0.6%
601,515
+350,000
+139% +$10M
CELL
36
DELISTED
PhenomeX Inc. Common Stock
CELL
$17.9M 0.53%
200,000
– –
KRON
37
DELISTED
Kronos Bio
KRON
$17.4M 0.52%
+583,436
New +$18.3M
SGMO
38
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$16.9M 0.5%
1,080,000
– –
FULC icon
39
Fulcrum Therapeutics
FULC
$283M
$14.5M 0.43%
1,241,176
-200,000
-14% -$2.26M
AMRS
40
CALL
DELISTED
Amyris Inc.
AMRS
$12.3M 0.37%
+2,000,000
New +$6.39M
SNDX icon
41
Syndax Pharmaceuticals
SNDX
$1.7B
$10M 0.3%
+450,000
New +$9.33M
BDTX icon
42
Black Diamond Therapeutics
BDTX
$99.7M
$9.28M 0.27%
289,395
– –
TPTX
43
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$9.14M 0.27%
75,000
– –
SEER icon
44
Seer Inc
SEER
$123M
$8.42M 0.25%
+150,000
New +$9.54M
ABCL icon
45
AbCellera Biologics
ABCL
$1.78B
$8.05M 0.24%
+200,000
New +$9.15M
DYN icon
46
Dyne Therapeutics
DYN
$4.71B
$7.77M 0.23%
370,000
– –
STOK icon
47
Stoke Therapeutics
STOK
$1.84B
$7.43M 0.22%
120,000
– –
FHTX icon
48
Foghorn Therapeutics
FHTX
$271M
$4.38M 0.13%
+216,216
New +$4.14M
BMY.RT
49
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$4.31M 0.13%
6,250,000
– –
CDAK
50
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$2.48M 0.07%
+76,688
New +$1.01M
1
2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Casdin Capital held 58 positions worth $3.38B, up 51% from $2.23B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Casdin Capital deployed $493M of net new capital in Q4 2020, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Exact Sciences: 1,485,149 shares worth $197M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $2.26M trimmed.

  • Casdin Capital's largest Q4 2020 buy was Exact Sciences: 1,485,149 shares worth $197M.
  • Casdin Capital added most to Invitae Corporation in Q4 2020, an estimated $156M increase.
  • Casdin Capital's biggest Q4 2020 reduction was Fulcrum Therapeutics, cutting an estimated $2.26M.
  • Casdin Capital fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $119M.
  • Casdin Capital's ten largest holdings make up 62% of its $3.38B portfolio in Q4 2020.
  • Casdin Capital opened 13 new positions and closed 6 in Q4 2020.
  • Casdin Capital's portfolio value rose 51% quarter-over-quarter to $3.38B.

Based on Casdin Capital's 13F filing for Q4 2020, filed 16 Feb 2021.